Current therapeutic guidelines for post-ET myelofibrosis patients comprise initiation of a JAK-2 inhibitor (e.g., ruxolitinib) and consideration of stem cell transplant as definitive treatment [11,12]. The gene discussed is JAK2; the disease is myelofibrosis.